BRUCE CLARK

Independent Consultant

From April 2017 to December 2020, Dr Clark was President and CEO of Medicago Inc. a company that uses a plant-based technology to develop and manufacture novel biotherapeutics with broad application to immunologically related disorders. These therapeutics include Virus Like Particle (VLP) vaccines, antibodies and various antigen display platforms.

Dr Clark led Medicago’s development and commercial strategies for the company’s Covid 19 vaccine. The company is based in Quebec City.Dr Clark’s has over 30 years of experience in the pharmaceutical and related industries. His experience includes:

  • January 2013 to February 2017; Vice President Regulatory and Scientific Affairs at Philip Morris International, responsible for global registration strategies for reduced risk products, external scientific engagement efforts, R&D Quality assurance and regulatory compliance
  • From August 2004 to December 2012; Senior Vice President Scientific and Regulatory Affairs for Apotex Inc. with global responsibility for regulatory and medical affairs including bioclinical and clinical development, R&D QA, project management and pharmacovigilance
  • Previous roles were as President of Medexus Inc., a Canadian specialty pharma company focused on rheumatology and women’s health, Vice President, Scientific Affairs for Sanofi Synthelabo Canada and Director, Regulatory Affairs, Glaxo Wellcome Inc. Canada

 LIVE ONLINE

20 May 2021

BOOK YOUR PLACE NOW